MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Disrupted Amplitude of Low-frequency Fluctuations and Causal Connectivity in Parkinson’s Disease with Apathy

    Y. Shen, J. Li, Y. Yuan, X. Wang, M. Wang, J. Wang, H. Zhang, L. Zhu, K. Zhang (Nanjing, China)

    Objective: We aimed to explore associated neural substrates changes in Parkinson’s disease (PD) with apathy via amplitude of low-frequency fluctuations (ALFF) and Granger Causality Analysis…
  • 2018 International Congress

    Applying Intervention Mapping methodologies to enhance Data Completeness in Movement Disorders-related Scales

    C. Goetz, S. Luo, G. Stebbins (Chicago, IL, USA)

    Objective: Describe the methodological steps and benchmarks needed to utilize Intervention Mapping as a strategy to enhance Data Completeness in Rating Scales relying on input…
  • 2018 International Congress

    Validation of the Parkinson’s Disease Pain Symptoms Scale (PD-PSS): An interim report

    D. Ciampi-de-Andrade, S. Perez-Lloret, N. Hollenstein, R. Curry, V. Rossetto Barbosa, G. Kägi, S. Hägele-Link, J. Walch, R. Gonzenbach, J-P. Lefaucheur, S. Beer, C. Möller, V. Mylius (Sao Paulo, Brazil)

    Objective: To explore the psychometric properties of the PD-PSS. Background: Evaluating pain in PD patients can be a difficult issue in the everyday clinical practice.…
  • 2018 International Congress

    Effects of droxidopa when measuring gait speed, kyphosis, and functional reach in Parkinson’s disease

    C. Kutz, L. Adams, E. Moncheski (Colorado Springs, CO, USA)

    Objective: To determine if droxidopa improves gait speed, kyphosis, and functional reach in Parkinson’s disease when added to routine care treatment. Background: Fall risk factors…
  • 2018 International Congress

    Botulinum toxin in Essential Hand Tremor – A Randomized Double-Blind Placebo-Controlled study with Customized Injection Approach

    S. Mittal, D. Machado, D. Richardson, D. Dubey, B. Jabbari (Bangalore, India)

    Objective: To evaluate the safety and efficacy of incobotulinumtoxinA (IncoA) injection for treatment of Essential Tremor (ET). Background: In essential tremor and Parkinson's Disease tremor,…
  • 2018 International Congress

    Improvement in Patient Perceived Quality of Life with DaxibotulinumtoxinA for Injection in Adults with Cervical Dystonia

    C. Comella, A. Brashear, J. Jankovic, D. Truong, A. Patel, M. Evatt, N. Kapa, Y. Liu, T. Nguyen-Cleary (Chicago, IL, USA)

    Objective: We describe the quality of life outcome from an open-label trial of daxibotulinumtoxinA for injection (Daxi) in cervical dystonia (CD) as measured by the…
  • 2018 International Congress

    Angiotensin-converting enzyme inhibitors are neuroprotective regarding APOE-mediated motor and non-motor experiences for Alzheimer’s dementia but not for dementia with Lewy bodies

    F. Oliveira, M. Miraldo, E. Castro-Neto, F. Machado, S. Almeida, S. Matas, P. Bertolucci, M. Naffah-Mazzacoratti (São Paulo, Brazil)

    Objective: To assess whether angiotensin-converting enzyme (ACE) inhibitors modulate associations of biofluid concentrations and activity of ACE with motor and non-motor experiences in dementia with…
  • 2018 International Congress

    Abnormal signaling along the non-canonical molecular cascade GRK6/β-arrestin2/Akt/GSK-3β in the putamen is associated with tardive dyskinesia following chronic haloperidol exposure in a primate model

    P. Blanchet, G. Hernandez, S. Mahmoudi, M. Cyr, J. Diaz, D. Levesque (Montreal, QC, Canada)

    Objective: To investigate the neurochemical basis of tardive dyskinesia (TD) in an experimental primate model. Background: TD is a potentially irreversible motor complication occurring in…
  • 2018 International Congress

    Demographic and Clinical Characteristics of Flunarizine Induced Parkinsonism: Nationwide Data Between 2000 and 2006 in Taiwan

    W. Lin, CY. Wei, HJ. Chen (ChangHua, Taiwan)

    Objective: The calcium channel blockers, such as flunarizine and cinnarizine, and rarely selective serotonin reuptake inhibitors and lithium can produce parkinsonism and tardive syndromes. Background:…
  • 2018 International Congress

    An evaluation of the availability and format of information provided to patients who have a new diagnosis of Parkinson’s disease (PD)

    L. Ebenezer, J. Price, H. Martin (Bridgend, United Kingdom)

    Objective: To evaluate if the information provided to a person with Parkinson’s (PwP) is relevant and appropriate for that individual. To also consider the need…
  • « Previous Page
  • 1
  • …
  • 100
  • 101
  • 102
  • 103
  • 104
  • …
  • 177
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley